Literature DB >> 27905835

Hemagglutination inhibiting antibody persistence 1 year after influenza vaccination in Korean children and adolescents.

Eun Kyeong Kang1, Byung Wook Eun2, Nam Hee Kim3, Yun Kyung Kim4, Jung Sub Lim5, Dong Ho Kim5.   

Abstract

This study aimed to assess the 1-y immunogenicity of influenza vaccines and the association between immunogenicity at 1 m and further influenza infections in children aged 6 m to 18 y. Serum hemagglutination inhibition (HI) antibody titers and GMTs were determined for the recommended influenza strains 0, 1, 6, and 12 m post-vaccination. The serological evidence of influenza infections were defined as the increase of HI titer (HI ≥1:40 and 4-fold rise). The seroprotection rates for strains A(H1N1), A(H3N2), and B were 91.2%, 87.6%, and 87.6%, respectively, at 1 month (n = 174). These rates were 76.5%, 64.7%, and 54.6%, respectively, at 12 m. The seroprotection rates and GMTs for influenza A(H1N1) and A(H3N2) were higher at 12 m than at 0 m (p < 0.05) but not for B. There were 39 subjects (42 cases) of serological influenza infections. Subjects with seroprotection at 1 m post-vaccination had showed fewer serologic A(H1N1) (10.1 vs 54.5%) and A(H3N2) (7.2 vs 38.1%) infections than the ones with HI titer <1:40 during follow-up (P < 0.01). In conclusion, influenza vaccines used during the 2008-09 season induced adequate 1-y immunogenicity for A(H1N1) and A(H3N2). The immunogenicity at one month after vaccination influenced further serological influenza infections.

Entities:  

Keywords:  1-year immunogenicity; children; hemagglutination inhibition; influenza vaccine; seroprotection rate

Mesh:

Substances:

Year:  2016        PMID: 27905835      PMCID: PMC5404370          DOI: 10.1080/21645515.2016.1259044

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  24 in total

Review 1.  Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis.

Authors:  Harish Nair; W Abdullah Brooks; Mark Katz; Anna Roca; James A Berkley; Shabir A Madhi; James Mark Simmerman; Aubree Gordon; Masatoki Sato; Stephen Howie; Anand Krishnan; Maurice Ope; Kim A Lindblade; Phyllis Carosone-Link; Marilla Lucero; Walter Ochieng; Laurie Kamimoto; Erica Dueger; Niranjan Bhat; Sirenda Vong; Evropi Theodoratou; Malinee Chittaganpitch; Osaretin Chimah; Angel Balmaseda; Philippe Buchy; Eva Harris; Valerie Evans; Masahiko Katayose; Bharti Gaur; Cristina O'Callaghan-Gordo; Doli Goswami; Wences Arvelo; Marietjie Venter; Thomas Briese; Rafal Tokarz; Marc-Alain Widdowson; Anthony W Mounts; Robert F Breiman; Daniel R Feikin; Keith P Klugman; Sonja J Olsen; Bradford D Gessner; Peter F Wright; Igor Rudan; Shobha Broor; Eric A F Simões; Harry Campbell
Journal:  Lancet       Date:  2011-11-10       Impact factor: 79.321

2.  Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children.

Authors:  Steven Black; Uwe Nicolay; Timo Vesikari; Markus Knuf; Giuseppe Del Giudice; Giovanni Della Cioppa; Theodore Tsai; Ralf Clemens; Rino Rappuoli
Journal:  Pediatr Infect Dis J       Date:  2011-12       Impact factor: 2.129

3.  Influenza and the rates of hospitalization for respiratory disease among infants and young children.

Authors:  H S Izurieta; W W Thompson; P Kramarz; D K Shay; R L Davis; F DeStefano; S Black; H Shinefield; K Fukuda
Journal:  N Engl J Med       Date:  2000-01-27       Impact factor: 91.245

4.  Clinical experience with inactivated, virosomal influenza vaccine.

Authors:  I A de Bruijn; J Nauta; W C M Cramer; L Gerez; A M Palache
Journal:  Vaccine       Date:  2005-07-08       Impact factor: 3.641

5.  The Japanese experience with vaccinating schoolchildren against influenza.

Authors:  T A Reichert; N Sugaya; D S Fedson; W P Glezen; L Simonsen; M Tashiro
Journal:  N Engl J Med       Date:  2001-03-22       Impact factor: 91.245

6.  Differences in antibody responses of individuals with natural infection and those vaccinated against pandemic H1N1 2009 influenza.

Authors:  Kwok-Hung Chan; Kelvin K W To; Ivan F N Hung; Anna J X Zhang; Jasper F W Chan; Vincent C C Cheng; Herman Tse; Xiao-Yan Che; Honglin Chen; Kwok-Yung Yuen
Journal:  Clin Vaccine Immunol       Date:  2011-03-16

7.  Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial.

Authors:  C B Bridges; W W Thompson; M I Meltzer; G R Reeve; W J Talamonti; N J Cox; H A Lilac; H Hall; A Klimov; K Fukuda
Journal:  JAMA       Date:  2000-10-04       Impact factor: 56.272

8.  Time to peak serum antibody response to influenza vaccine.

Authors:  S Rastogi; P A Gross; J Bonelli; S Dran; R A Levandowski; C Russo; M E Weksler; D Kaye; M Levison; E Abrutyn
Journal:  Clin Diagn Lab Immunol       Date:  1995-01

9.  Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season.

Authors:  Edward A Belongia; Burney A Kieke; James G Donahue; Robert T Greenlee; Amanda Balish; Angie Foust; Stephen Lindstrom; David K Shay
Journal:  J Infect Dis       Date:  2009-01-15       Impact factor: 5.226

10.  Long-term immunogenicity of a virosomal subunit inactivated influenza vaccine in children with asthma.

Authors:  Gianvincenzo Zuccotti; Antonella Amendola; Alessandra Viganò; Elena Pariani; Alessandra Zappa; Laura Pogliani; Vania Giacomet; Antonino Savarino; Alberto Podestà; Amilcare Rottoli; Elisabetta Tanzi; Alessandro Zanetti; Giovanni Radaelli
Journal:  Vaccine       Date:  2007-07-27       Impact factor: 3.641

View more
  2 in total

1.  Evaluation of Waning Immunity at 6 Months after Both Trivalent and Quadrivalent Influenza Vaccination in Korean Children Aged 6-35 Months.

Authors:  Jee Hyun Lee; Hye Kyung Cho; Ki Hwan Kim; Jina Lee; Yae Jean Kim; Byung Wook Eun; Nam Hee Kim; Dong Ho Kim; Dae Sun Jo; Hwang Min Kim; Yun Kyung Kim
Journal:  J Korean Med Sci       Date:  2019-12-02       Impact factor: 2.153

2.  Influenza A(H1N1)pdm09 but not A(H3N2) virus infection induces durable sero-protection: results from the Ha Nam Cohort.

Authors:  Le Nguyen Minh Hoa; Sheena G Sullivan; Le Quynh Mai; Arseniy Khvorov; Hoang Vu Mai Phuong; Nguyen Le Khanh Hang; Pham Quang Thai; Le Thi Thanh; Louise Carolan; Dang Duc Anh; Tran Nhu Duong; Juliet E Bryant; H Rogier van Doorn; Heiman F L Wertheim; Peter Horby; Annette Fox
Journal:  J Infect Dis       Date:  2020-06-02       Impact factor: 7.759

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.